

Intranasal Drug Delivery: Market Research Report

<https://marketpublishers.com/r/I2C4E901E51EN.html>

Date: December 2018

Pages: 239

Price: US\$ 5,600.00 (Single User License)

ID: I2C4E901E51EN

Abstracts

This report analyzes the US Market for Intranasal Drug Delivery in US\$ Million by the following Therapeutic Areas: Allergic Infections, Analgesics, Osteoporosis, and Vaccinations.

Annual estimates and forecasts are provided for the period 2016 through 2024.

Also, a five-year historic analysis is provided for this market.

Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

The report profiles 64 companies including many key and niche players such as -

Aegis Therapeutics LLC

AptarGroup, Inc.

AstraZeneca Plc

Becton Dickinson and Company

GlaxoSmithKline Plc

Johnson & Johnson Inc.

Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definition and Scope of Study

II. A US MARKET REPORT

1. INDUSTRY OVERVIEW

A Prelude

Intranasal Cavity: An Attractive Drug Delivery Route to Cross the Blood Brain Barrier

Factors Inhibiting Nose-to-Brain Transportation of Drugs

Drug's Physico-Chemical Properties

Drug Dose, Concentration & Volume Administration

Mucociliary Clearance

Existence of Enzymatic Activity

Animal Species: Variations in Nasal Mucosa

Overcoming Barriers to Nose-to-Brain Delivery of Drugs

Prodrug Technique

Innovative Formulation

Use of Enzyme Inhibitors & Absorption Enhancers

Bioavailability: An Important Facet of Intranasal Drug Delivery

Chemical Modification

Transient Modification & Limited Enzymatic Activity

Bioavailability of Large Molecules

Bio-Adhesive Polymers: Useful in Increasing Drug Absorption

Outlook

Nasal Drug Delivery Devices & Equipment

Preservative Free Systems (PFS)

Traditional Vs. Advanced Intranasal Drug Formulation Types

Type of Nasal Delivery Vehicles with Select Therapeutic Agents and Area of Application

2. MARKET DRIVERS, TRENDS & ISSUES

Burgeoning Geriatric Populace Spurs Growing Demand for Intranasal Drug Therapies

Table 1. Global Population Estimates (in Billion): 2000-2050P (includes corresponding Graph/Chart)

Table 2. Aging (65+) Demographics as a Percentage of Total Population for Major Countries: 2010, 2015 & 2020 (includes corresponding Graph/Chart)

Table 3. Global Aging Population (in Thousands) by Age Group: 2010, 2015, 2025 & 2050 (includes corresponding Graph/Chart)

Table 4. Global Population Statistics for the 65+ Age Group (Male & Female) for Major Countries/Regions: 2015 (includes corresponding Graph/Chart)

Table 5. Global Life Expectancy at Age 60 and 80 Years: 2010-2015; 2020-2025; and 2045-2050 (includes corresponding Graph/Chart)

Table 6. Life Expectancy for Select Countries in Number of Years: 2015 (includes corresponding Graph/Chart)

Table 7. US Geriatric Population by Age Group (2000, 2005, 2010, 2015, 2020, 2030, 2040, & 2050): Percentage Share of US Population of Senior Citizens of Age Group 65-74 Years, 75- 84 Years, and 85 Years & Above (includes corresponding Graph/Chart)

Nasal Drug Delivery Offers New Opportunities for Drug Developers as Patent Cliffs Usher in Dusk of Blockbuster Era

Table 8. Top Nasal Inhalers, Sprays, and Drops Brands in the US (2017): Percentage Share Breakdown of Dollar Sales for Afrin No Drip, Afrin, Arm & Hammer Simply Saline, Zicam, Neilmed Sinus Rinse, Ayr, Private Labels, and Others (includes corresponding Graph/Chart)

Pharmaceutical and Medical Device Companies Vying to Develop New Intranasal Therapeutics for Allergic Rhinitis Patients

Table 9. Prevalence Percentage of COPD, Asthma, and Allergic Rhinitis for Select Countries: 2016 (includes corresponding Graph/Chart)

Table 10. The US Allergic Rhinitis Patient Population by Disease Severity (2016): Percentage Breakdown of Patient Pool for Mild Intermittent, Mild Persistent, Moderate-severe Intermittent, and Moderate-severe Persistent (includes corresponding Graph/Chart)

The US - FDA Approved Intranasal Corticosteroids (INAC) and Intranasal Antihistamines (INAH) for Treating Allergic Rhinitis

The US - FDA Approved Nasal Spray Medication Types (excluding INAC & INAH) for Allergic Rhinitis Treatment

Table 11. Global Respiratory Drugs Market by Category (2015 & 2020): Percentage Breakdown of Dollar Values for COPD Therapies, Inhaled Steroids, Long Acting Beta Agonists, Nasal Steroids, and Others (includes corresponding Graph/Chart)

The US - FDA Approved Intranasal Corticosteroids (INAC) and Intranasal Antihistamines (INAH) for Treating Allergic Rhinitis

The US - FDA Approved Nasal Spray Medication Types (excluding INAC & INAH) for Allergic Rhinitis Treatment

Intranasal Corticosteroids – A Potential Treatment for Debilitating Chronic Rhinosinusitis Disease

Select Intranasal Corticosteroid Brands for Adult and Pediatric Usage

Self-Administration of Drugs Brings Intranasal Drug Delivery into the Spotlight

Innovation in Drug Delivery: A Talisman for Success

Active Pharmaceutical Ingredients Used in Formulations for Nasal Drug Delivery with Related Indications

Controlled Release Technology Is the Buzz Word

Target-Specific Delivery Devices: Of Critical Value

Safety and Cost: Primary Growth Drivers

Increasing R&D Unlocks New Therapeutic Areas for Nasal Drug Delivery

Intranasal Therapeutics Delivery – A High Potential Method for Treating CNS Diseases

Intranasal Insulin Delivery Offers Strong Clinical Significance

Inhaled Insulin Market Challenged by Low Acceptance Levels

Intranasal Delivery of Anti-emetic Agent Metoclopramide Hydrochloride Validated by Study on Rodents

Intranasal Delivery of Peptide-Based Pharmaceuticals

Select Protein, Peptide & Non-Peptide Drugs Available as Nasal Spray Solutions in the Marketplace

Tight Junction Biology: A Key Speed Breaker in Commercialization

RNA Interference (RNAi): A Tool to Manipulate Tight Junctions

Research Studies Authenticate Benefits of Bi-Directional Nasal Drug Delivery

Growing Interest for Preservative-free Nasal Spray Formulations

Multi-Dose Containers Developed to Offer Resistance against Microbial Contamination

3. RECENT RESEARCH & DEVELOPMENT INITIATIVES

OptiNose XHANCE

Nose-to-Brain Drug Delivery

OPN-300 – A Potential Alternative for Many Brain Disorders

Orexin-A Replacement for Treating Narcolepsy

Advanced Nanoparticle Nasal Spray to Enable Drug Delivery to Brain

OptiNose Develops Innovative Treatment Option for Sinusitis

Intranasal Administration of ATX-LIPO for Brain Targeting – A Promising Therapy for ADHD

Noteworthy Registered and Published Clinical Trials on Intranasal Psychotropics

Focused Ultrasound Leveraged to Enhance Intranasal Drug Delivery

Evoke Pharma Develops EVK-001 Intranasal Metoclopramide Delivery System for Treating Gastroparesis

Smart Polymers with Temperature, pH or Ionic Response in Nasal drug Delivery

Chitosan Thermosensitive Biogels Evaluated for Intranasal Delivery of CNS Drugs

Select Nasal Drug Absorption Enhancers and Related Mechanisms

Dendrimers to Enhance Water-solubility of Antipsychotic Drugs for Intranasal Administration

Naloxone Hydrochloride Nasal Sprays Provides a Powerful Alternative for Opioid Overdose Medications

OptiNose ONZETRA Xsail (AVP-825) – An Innovative Breath-Powered Intranasal Delivery System for Migraine Treatment

Clinical Study Demonstrates Faster Antidepressant Effects of Intranasal Ketamine

Intranasal Aerosol Dose of PH94B Investigated for Treating Social Anxiety Disorder (SAD)

4. TECHNOLOGY OVERVIEW

Intranasal Drug Delivery: A Descriptive Exposition

Nasal Physiology

Challenges Involved In Formulating Nasal Drugs

The Importance of Bioadhesion

Overview of the Traditional Drug Administration Routes, Molecular Weight Capabilities, and Dosage Range

Intranasal Drugs – Prescription (Rx) and Over-the-Counter (OTC)

Differences between Systemic Delivery and Local Effects

Nasal Powders Vs. Sprays

Nasal Drug Delivery Devices

Types of Drug Delivery Devices

Droppers

Sprays

Aerosol Containers/Inhalers

Pumps

Nasal Aspirators

Intranasal Drug Delivery Vis-à-vis Other Delivery Techniques

Limitations of Intranasal Drug Delivery

Allergy

Definition

Symptoms

Allergic Rhinitis

Nasal Allergies

5. NASAL DELIVERED DRUGS: AN OVERVIEW

Nasal Drugs for Allergies

Corticosteroid Nasal Sprays

Flonase

Patanase

Beconase

Other Nasal Corticosteroid Drugs

Antihistamine Nasal Sprays

Astelin Nasal Spray

Otrivin Nasal Spray

Livostin Nasal Spray

Other Nasal Antihistamine Drugs

Select Brands of Allergy Relievers

Nasal Drugs for Postmenopausal Osteoporosis

Calcitonin–Salmon Nasal Spray

Miacalcin Nasal Spray

Fortical Nasal Spray
Intranasal Pain Management Drugs
Stadol Nasal Spray
Imitrex
Migranal
Zolmitriptan Nasal Spray
Intranasal Analgesics for Treating Migraine
Intranasal Vaccination
Process of Intranasal Immunization'LAIV' Nasal Spray Flu Vaccine
FluMist Vaccine from MedImmune
Intranasal Drugs for Sexual Dysfunction
Nasal Spray for Treating Vitamin B12 Deficiency
Nasal Spray for Aiding Smoking Cessation

6. PRODUCT DEVELOPMENTS, APPROVALS & INTRODUCTIONS

FDA Approves OptiNose XHANCE Nasal Spray
Splintek Launches Intra-Nasal Sleep Inhaler
Allergan Receives Market Authorization for TrueTear
St. Renatus Launches Kovanaze Nasal Spray
Perrigo and West-Ward Pharmaceuticals Launch Generic Store Brand Flonase
Nemera Launches Advancia Multi-Dose Nasal Spray System
Adapt Pharma Launches Narcan Opioid Antagonist
Apotex Unveils Generic Version of Nasonex
McNeil Consumer Healthcare Rolls Out OTC RHINOCORT
OptiNose Bags FDA Approval for ONZETRA Xsail
Avanir's Onzetra Secures FDA Approval
FDA Approves Lannett's Sumatriptan Nasal Spray
Meda's Dymista Bags Health Canada's Approval
Endo Pharmaceuticals Announces Availability of NATESTO
AstraZenca Canada Unveils FluMist for Children
Perrigo Receives US FDA Approval for Generic Version of Sun Pharma's Kenalog
GSK Rolls Out OTC Version of Flonase Allergy Relief
Upsher-Smith Publishes Data from USL261 Phase 1 Trials
KemPharm Concludes KP201/APAP's Human Abuse Liability Program
OptiNose Publishes Results of OPN 375's Phase III Trial
NanoBio's Genital Herpes Vaccine Proven Effective
Recro Pharma Releases Further Details of Dex-IN's Phase II Clinical Trial
Evoke Announces Phase III Trials of EVK-001

FDA Accepts Filing of TARSA's TBRIA
FDA Accepts Review of Pfizer's ALO-02
Breckenridge Bags FDA Approval for Azelastine HCl Nasal Solution
ZOMIG Gets FDA Approval

7. RECENT INDUSTRY ACTIVITY

Opiant Pharmaceuticals to Pursue Development of Intranasal Nalmefene
Egalet and OraPharma to Co-Promote SPRIX Nasal Spray
Aegis Develops Hydromorphone Nasal Spray
Emergent Biosolutions to Develop Intranasal Spray for Treatment of Cyanide Poisoning
Aptar Pharma to Manufacture Child-Resistant Nasal Pumps in North America
Therapix and Yissum Sign License for Cannabinoid Nasal Drug Delivery Technology
Impel NeuroPharma and Camargo Pharmaceutical Services Sign Service Agreements
Egalet Inks Deal With Septodont for SPRIX Promotion
Lilly Acquires Intranasal Glucagon Rights
UAE recalls Otrivin Nasal Spray Batches
Eli Lilly Acquires Rights for Innovent's Intranasal Glucagon
AstraZenca Commences Shipment of FluMist

8. FOCUS ON SELECT PLAYERS

Aegis Therapeutics LLC (USA)
AptarGroup, Inc. (USA)
AstraZeneca Plc. (UK)
MedImmune, Inc. (USA)
Becton Dickinson and Company (USA)
GlaxoSmithKline Plc. (UK)
Johnson & Johnson Inc. (USA)
Marina Biotech, Inc. (USA)
Merck & Co., Inc. (USA)
Nemera (France)
Novartis AG (Switzerland)
OptiNose US Inc. (USA)
Pfizer, Inc. (USA)
Valeant Pharmaceuticals International, Inc. (Canada)

9. US MARKET ANALYTICS

Table 12. The US Recent Past, Current & Future Analysis for Intranasal Drug Delivery by Therapeutic Area - Allergic Infections, Analgesics, Osteoporosis, and Vaccinations Markets Independently Analyzed by Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 13. The US Historic Review for Intranasal Drug Delivery by Therapeutic Area - Allergic Infections, Analgesics, Osteoporosis, and Vaccinations Markets Independently Analyzed by Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 14. The US 14-Year Perspective for Intranasal Drug Delivery by Therapeutic Area - Percentage Breakdown of Values Sales for Allergic Infections, Analgesics, Osteoporosis, and Vaccinations Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 64 (including Divisions/Subsidiaries - 81)

The United States (48)

Canada (4)

Japan (2)

Europe (17)

 France (2)

 Germany (4)

 The United Kingdom (4)

 Rest of Europe (7)

Asia-Pacific (Excluding Japan) (7)

Middle East (2)

Latin America (1)

I would like to order

Product name: Intranasal Drug Delivery: Market Research Report

Product link: <https://marketpublishers.com/r/l2C4E901E51EN.html>

Price: US\$ 5,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l2C4E901E51EN.html>